CN113812395A

CN113812395A - Erythrocyte preservation solution

Info

Publication number: CN113812395A
Application number: CN202111123555.1A
Authority: CN
Inventors: 程若愚; 何流; 刘自诚; 张艳; 唐涛
Original assignee: Hefei Tianyi Institute Of Biological Technology Co ltd
Current assignee: Hefei Tianyi Institute Of Biological Technology Co ltd
Priority date: 2021-09-24
Filing date: 2021-09-24
Publication date: 2021-12-21

Abstract

The invention provides a red blood cell preservation solution, which adopts a phosphate and carbonate mixed buffer system and comprises the following components in percentage by weight: 30-40mg/mL of glucose hydrate, 0.3-0.5mg/mL of adenine, 8-12mg/mL of mannitol, 0.03-0.05mg/mL of disodium hydrogen phosphate, 0.05-0.15mg/mL of sodium bicarbonate, 5-15mg/mL of sodium citrate, 0.3-0.7mg/mL of chloramphenicol and 2-4mg/mL of sodium chloride. According to the invention, carbonate is added into the buffer system of the erythrocyte preservation solution, so that the damage of low-temperature storage can be effectively reduced.

Description

Erythrocyte preservation solution

Technical Field

The invention relates to the technical field of erythrocyte preservation, in particular to erythrocyte preservation solution.

Background

The antigen-antibody experiment before human blood transfusion is the basis for ensuring the safety of blood transfusion, the existing antibody is standardized by a monoclonal technology, and red blood cells containing the antigen can only come from a human body and cannot be synthesized artificially. Therefore, prolonging the storage time of human erythrocytes as much as possible is one of the key points in the study of blood group laboratories. The existing method for preserving red blood cells in a laboratory is to put the red blood cells into red blood cell preserving fluid and store the red blood cells in an environment of 4 ℃, so that the metabolic rate of the red blood cells can be reduced, and the preservation time can be prolonged.

The existing erythrocyte preservation solution can generally preserve reagent erythrocytes for about 90 days, but generally, the erythrocytes begin to have different degrees of hemolysis and color change after being preserved for more than 60 days. This is because red blood cells have two major problems during storage: 1. a decrease in the oxygen carrying capacity of the red blood cells; 2. cells are damaged in refrigerated environments. The imbalance in nitric oxide NO equilibrium is the major cause of the reduced oxygen transport capacity of erythrocytes, and NO is a key vascular extender, forming the S-nitro group in combination with hemoglobin Hb on cysteine-93. Hemoglobin SNO-Hb is the main mode for storing and transporting oxygen, but free hemoglobin FHb in blood oxidizes NO at a high speed into nitrate, the NO is greatly consumed, and oxygen supply is insufficient for red blood cells, and hemolysis occurs.

In patent CN105028389B issued by the national intellectual property office in 2017, 9, month and 22, the preservation solution is lack of a membrane protective agent, free hemoglobin is not treated, and the problem of low-temperature storage damage is not solved.

Disclosure of Invention

Aiming at the defects of the existing erythrocyte preservation solution, the invention provides the erythrocyte preservation solution which can protect erythrocytes from being damaged during low-temperature storage.

A erythrocyte preservation solution adopts a mixed buffer system of phosphate and carbonate.

Preferably, the erythrocyte preservation solution comprises the following components in percentage by weight:

30-40mg/mL of glucose hydrate, 0.3-0.5mg/mL of adenine, 8-12mg/mL of mannitol, 0.03-0.05mg/mL of disodium hydrogen phosphate, 0.05-0.15mg/mL of sodium bicarbonate, 5-15mg/mL of sodium citrate, 0.3-0.7mg/mL of chloramphenicol and 2-4mg/mL of sodium chloride. The sodium bicarbonate herein may be replaced by other suitable carbonates.

Preferably, the composition also comprises 8-12umol/L of haptoglobin.

The invention has the beneficial effects that: carbonate is added into a buffer system, so that low-temperature storage damages (HSLs) can be effectively reduced, meanwhile, the haptoglobin Hp is added, and can be specifically combined with free hemoglobin FHb in blood, so that NO in red blood cells cannot be oxidized into nitrate at high speed, the oxygen conveying capacity of the cells is improved, and the survival time of the red blood cells is prolonged; therefore, the quality guarantee period of the reagent red blood cells is prolonged, and the quality of the red blood cells in the test is improved, so that the test result is closer to the real result.

Drawings

FIG. 1 is a graph showing the results of experiments on time and hemolysis rate of examples 1-4;

FIG. 2 is a graph showing the results of the experiments of examples 5 to 8 with respect to time and hemolysis rate;

FIG. 3 is a graph showing the results of the experiments of examples 9 to 12 with respect to time and hemolysis rate.

Detailed Description

The technical solutions in the embodiments of the present invention are clearly and completely described below with reference to the accompanying drawings and the specific embodiments, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments that can be derived by one of ordinary skill in the art from the embodiments given herein are intended to be within the scope of the present invention.

Examples 1 to 4

The components and contents of the erythrocyte preservation solution are shown in the following table 1, and the test results of the examples 1 to 4 on the time and the hemolysis rate are shown in the figure 1.

TABLE 1

As can be seen from FIG. 1, example 1, which added sodium bicarbonate and haptoglobin together, had the longest storage period and the best storage effect, and after 100 days, the hemolysis rate did not substantially increase; example 3 with addition of haptoglobin only; example 2 with addition of sodium bicarbonate only was repeated again; the hemolysis rate of example 4, with neither sodium bicarbonate nor haptoglobin added, was consistently higher than that of examples 1-3.

Examples 5 to 8

The components and contents of the erythrocyte preservation solution are shown in the following table 2, and the test results of the examples 5 to 8 on the time and the hemolysis rate are shown in the figure 2.

TABLE 2

The results of the experiments of examples 5-8 with respect to time and hemolysis rate are shown in FIG. 2, which concludes the same as in examples 1-4.

Examples 9 to 12

The components and contents of the erythrocyte preservation solution are shown in the following table 3, and the test results of examples 9-12 on time and hemolysis rate are shown in fig. 3.

TABLE 3

The results of the experiments of examples 9-12 with respect to time and hemolysis rate are shown in FIG. 3, which concludes the same as in examples 1-4.

Through analysis, the haptoglobin Hp is added, and can be specifically combined with free hemoglobin FHb in blood, so that NO in red blood cells cannot be oxidized into nitrate at high speed, the oxygen conveying capacity of the cells is improved, and the survival time of the red blood cells is prolonged; meanwhile, carbonate is added into the buffer system, so that low-temperature storage damages (HSLs) can be effectively reduced, the quality guarantee period of the reagent red blood cells is prolonged, the quality of the red blood cells during the test is improved, and the test result is closer to the real result.

Finally, it should also be noted that the above list is only one specific embodiment of the invention. It is obvious that the invention is not limited to the above embodiments, but that many variations are possible. All modifications which can be derived or suggested by a person skilled in the art from the disclosure of the present invention are to be considered within the scope of the invention.

Claims

1. A erythrocyte preservation solution is characterized in that a phosphate and carbonate mixed buffer system is adopted.

2. The erythrocyte preservation solution according to claim 1, which comprises the following components in percentage by weight:

30-40mg/mL of glucose hydrate, 0.3-0.5mg/mL of adenine, 8-12mg/mL of mannitol, 0.03-0.05mg/mL of disodium hydrogen phosphate, 0.05-0.15mg/mL of sodium bicarbonate, 5-15mg/mL of sodium citrate, 0.3-0.7mg/mL of chloramphenicol and 2-4mg/mL of sodium chloride.

3. The erythrocyte preservation solution of claim 2, further comprising 8-12umol/L haptoglobin.